These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32538346)

  • 1. Health Canada's Proposal to Accelerate New Drug Reviews.
    Lexchin J
    Healthc Policy; 2020 May; 15(4):26-34. PubMed ID: 32538346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The characteristics and fulfillment of conditional prescription drug approvals in Canada.
    Law MR
    Health Policy; 2014 Jun; 116(2-3):154-61. PubMed ID: 24703857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis.
    Lexchin J
    BMJ Open; 2018 Aug; 8(8):e023605. PubMed ID: 30166310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
    Lexchin J
    Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis.
    Lexchin J
    Int J Health Serv; 2019 Apr; 49(2):294-305. PubMed ID: 30587064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study.
    Lexchin J
    PLoS One; 2020; 15(11):e0240966. PubMed ID: 33137156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: Expedited Regulatory Review of Low-Value Drugs.
    Darrow JJ; Beall RF
    Healthc Policy; 2020 May; 15(4):35-40. PubMed ID: 32538347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
    Rawson NSB
    Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The timeliness of new drug approvals in Canada.
    Rawson NS
    Int J Health Serv; 1995; 25(1):153-65; discussion 167-71. PubMed ID: 7794387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who needs faster drug approval times in Canada: the public or the industry?
    Lexchin J
    Int J Health Serv; 1994; 24(2):253-64. PubMed ID: 8034392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Canada's use of priority review status for drugs for unmet needs.
    Rawson NS
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):391-5. PubMed ID: 26260656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.
    Lexchin J; Ahmed T
    CMAJ Open; 2015; 3(3):E286-91. PubMed ID: 26442227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study.
    Lexchin J
    PLoS One; 2024; 19(8):e0308118. PubMed ID: 39088553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.